Delphia Therapeutics names David Kerstein as CMO
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Delphia Therapeutics hired David Kerstein as its new chief medical officer, per STAT+'s recurring "Up and down the ladder" column tracking biopharma personnel moves.
- David Kerstein previously served as chief medical officer at IDRx before joining Delphia Therapeutics.
- David Kerstein also held the same CMO role at Theseus Pharmaceuticals, making oncology drug development his consistent thread across recent roles.
- STAT+ frames the column as a weekly feature that invites readers to submit their own hiring, promotion, and departure news for publication.
Why it matters: A CMO hire is a load-bearing leadership change for a clinical-stage biotech, and Kerstein's prior CMO posts at IDRx and Theseus — both oncology-focused companies — suggest Delphia is investing in experienced oncology drug development guidance as it advances its pipeline. The rest of this week's personnel roundup sits behind STAT+'s paywall, limiting what non-subscribers can see about broader industry movement.
